AlphAIalphai — Financial news for AI agents
BenzingaOCT 33 min read$ANGO

AngioDynamics Eyes Growth Despite Tariffs - AngioDynamics (NASDAQ:ANGO)

AngioDynamics, Inc. ( NASDAQ:ANGO ) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.

Original reporting
Benzinga · Triveni Kothapalli
Published Oct 3, 2025, 4:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 3, 2025, 5:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
AngioDynamics Eyes Growth Despite Tariffs - AngioDynamics (NASDAQ:ANGO) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$ANGOBullishMed
01

Why it matters

The company's ability to outperform despite tariffs suggests operational resilience and potential for sustained growth.

02

Market read

The positive earnings report enhances investor confidence in AngioDynamics and the Med-Tech sector.

03

What to watch

Possible slowdown in hospital procurement cycles or regulatory delays affecting Med-Tech sales.

Timing: Immediate to short-term (next 1-3 months)

Background

AngioDynamics reported better-than-expected earnings, driven by growth in its Med-Tech segment, despite ongoing tariffs affecting imports.

Company-level read

Ticker impact

$ANGOBullishHigh confidence
Context

Primary focus of the news is AngioDynamics (NASDAQ:ANGO), which posted strong quarterly results and raised FY2026 guidance.

Expected impact

Moderate upward movement in the near term (1-3 months).

Evidence & confidence

Strong quarterly results and upward guidance suggest solid operational performance, supported by positive market sentiment.

Market effects

Sector

Positive outlook for Med-Tech sector due to strong earnings and guidance

Regional

Limited regional impact; primarily US-focused

Global

Moderate, as Med-Tech is a global industry but news is US-centric

Counterpoint

What could challenge this read

Potential overestimation of growth; tariffs and supply chain issues could dampen future performance.

Key entities

  • Company
    AngioDynamics

    A provider of minimally invasive medical devices and therapies.

Read at source← All news

Related articles

JUL 21
$ANGOMed

AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.

yahoo.com7 min
AUG 8
$BKRMed

Baker Hughes extends long-term service deal for Nigeria LNG Train 7

Baker Hughes said it won a 13-year lifecycle services deal with Nigeria LNG for turbomachinery at NLNG’s Train 7 expansion on Bonny Island. The scope covers heavy-duty gas turbines, centrifugal compressors, remote monitoring via Baker Hughes’ digital platform, and local support. Train 7 is expected to raise capacity from 22 to 30 MMtpa.

worldoil.com3 min
AUG 8
$BKRMed

Baker Hughes wins subsea systems contract for Angola's Greater PAJ field

Baker Hughes said it won a contract from Azule Energy to supply subsea production systems for the Greater PAJ ultra-deepwater project offshore Angola. Scope includes horizontal subsea trees, control modules, workover control systems and related equipment plus installation and support. Greater PAJ is expected to start producing in 2029 via an FPSO processing up to 95,000 bpd, with deliveries starting in 2027.

worldoil.com4 min
AUG 8
$WENMed

57-year-old Burger chain closed 28 restaurants, 100s more coming

Wendy’s (WEN) said it closed 28 restaurants and expects to close 5% to 6% of U.S. units (about 289 to 358) in 1H 2026, with possible additional selective closures. The company reported 2Q FY2026 systemwide sales down 6.5% YoY, U.S. systemwide down 8.2%, and U.S. same-restaurant sales down 7%. Wendy’s launched a turnaround plan and withdrew its 2026 outlook.

yahoo.com6 min